Estrogen Helps Drive Distinct, Aggressive Form of Prostate Cancer

May 28, 2008

Using a breakthrough technology, researchers led by a Weill Cornell Medical College scientist have pinpointed the hormone estrogen as a key player in about half of all prostate cancers.

Estrogen-linked signaling helps drive a discrete and aggressive form of the disease caused by a chromosomal translocation, which in turn results in the fusion of two genes.

"Fifty percent of prostate cancers harbor a common recurrent gene fusion, and we believe that this confers a more aggressive nature to these tumors," explains study senior author Dr. Mark A. Rubin, professor of pathology and laboratory medicine, and vice chair for experimental pathology at Weill Cornell Medical College. Dr. Rubin is also attending pathologist at NewYork-Presbyterian Hospital/Weill Cornell Medical Center.

"Interfering with this gene fusion - or its downstream molecular pathways - will be crucial in the search for drugs that fight the disease. Based on our new data, we now believe that inhibiting estrogen may be one way of doing so," he says.
The findings are published in the May 27 online edition of the Journal of the National Cancer Institute. Dr. Rubin conducted the study while at the Brigham and Women's Hospital and in collaboration with Dr. Todd Golub and other members of the Broad Institute of MIT and Harvard, in Cambridge, Mass. His team is now continuing this line of research at Weill Cornell.

Dr. Rubin, along with researchers at the University of Michigan, first discovered and described the common fusions between the TMPRSS2 and ETS family member genes subset of prostate cancer in the journal Science in 2005. "The discovery showed that these malignancies occur after an androgen (male hormone)-dependent gene fuses with an oncogene - a type of gene that causes cancer," he explains.

Experts have long understood that male hormones help spur prostate cancer - in fact, androgen-deprivation therapy is a first-line treatment against the disease. And yet the disease can progress despite androgen reduction, suggesting that other pathways might be at work.

"So, we wanted to learn more - what is the genetic and molecular 'fingerprint' of this aggressive subset of prostate tumor?" Dr. Rubin says.

Answering that question required the analysis of 455 prostate cancer samples from trials in Sweden and the United States that were conducted as far back as the mid-1970s.

"These samples were placed in fixative and not frozen, so we needed new methods of retrieving the genetic information," Dr. Rubin says. To do so, his team led by co-lead authors Dr. Sunita Setlur and Dr. Kirsten Mertz developed an innovative technology for effectively "reading" the gene transcription profiles hidden in the samples.

"That led us to perform the largest gene-expression microarray analysis yet conducted in prostate cancer research, amassing information on more than 6,000 genes," Dr. Rubin says. "This allowed us to obtain a robust, 87-gene expression 'signature' that distinguishes fusion-positive TMPRSS2-ERG cancers from other prostate malignancies."

A close analysis of the signature yielded a surprise: that estrogen-dependent molecular pathways appear to play a crucial role in regulating (and encouraging) this aggressive subset of prostate cancer.

While estrogen is typically thought of as a "female" hormone, men produce it as well.

"Now, we show for the first time that this natural estrogen can stimulate the production of the cancer-linked TMPRSS2-ERG transcript, via the estrogen receptor (ER)-alpha and ER-beta. These receptors are found on the surface of some prostate cancer cells," Dr. Rubin explains.

The finding could have implications for prostate cancer research, including drug development. According to Dr. Rubin, "We now believe that agents that dampen estrogen activity (ER-beta antagonists) could inhibit fusion-positive prostate cancers. Alternatively, any intervention that boosts estrogen activity (ER-alpha) might also give a boost to these aggressive malignancies."

Research into just why fusion-positive prostate cancers are so aggressive - and potential molecular drug targets to help curb that aggression - will continue under Dr. Rubin's direction at Weill Cornell, in collaboration with members of his group and with computational biologist Dr. Francesca Demichelis.

"The technological achievement of using fixed samples that were up to 30 years old is significant," Dr. Rubin says. "In the future, we hope to explore banked tissues from clinical trials to help understand why they failed. This should lead to insight for designing the next trial."

This work was funded by the U.S. National Institutes of Health, a Prostate SPORE grant at the Dana-Farber/Harvard Cancer Center, Swiss Foundation for Medical-Biological Grants SSMBS, U.S. Department of Defense and the Prostate Cancer Foundation.

Co-researchers include study co-lead authors Dr. Sunita Setlur and Dr. Kirsten Mertz of Brigham and Women's Hospital and Harvard Medical School, Boston; Dr. Yujin Hoshida and Dr. Todd Golub of the Broad Institute and the Dana-Farber Cancer Institute, Boston; Dr. Francesca Demichelis of Weill Cornell Medical College and Harvard Medical School, Boston; Dr. Mathieu Lupien of the Dana-Farber Cancer Institute; Dr. Sven Perner and Jeff Tang of Weill Cornell Medical College; Andrea Sboner of Yale University, New Haven; Dr. Yudi Pawitan and Dr. Katja Fall of the Karolinska Institutet, Stockholm, Sweden; Dr. Ove Andren, Dr. Jan-Erik Johansson and Dr. Swen-Olof Andersson, of Orebro University Hospital, Orebro, Sweden; Laura A. Johnson of Brigham and Women's Hospital, Boston; Dr. Hans-Olov Adami, of Karolinska Institutet, Sweden, and Harvard School of Public Health, Boston; Dr. Stefano Calza, of the Karolinska Institutet, Sweden, and the University of Brescia, Italy; Dr. Arul M. Chinnaiyan, Dr. Daniel Rhodes and Scott Tomlins, of the University of Michigan Medical School, Ann Arbor; Dr. Lorelei Mucci and Dr. Meir Stampfer of Harvard Medical School, Harvard School of Public Health and Brigham and Women's Hospital, Boston; Dr. Philip Kantoff of Dana-Farber Cancer Institute and Harvard Medical School; Dr. Eberhard Varenhorst, of University Hospital Linkoping, Sweden; and Dr. Myles Brown of the Dana-Farber Cancer Institute.

Dr. Mark A. Rubin, Dr. Francesca Demichelis, Dr. Sven Perner, Dr. Arul M. Chinnaiyan and Scott Tomlins are co-inventors on a patent filed by the University of Michigan and the Brigham and Women's Hospital, covering the diagnostic and therapeutic fields for ETS fusions in prostate cancer.


Weill Cornell Medical College

Weill Cornell Medical College, Cornell University's medical school located in New York City, is committed to excellence in research, teaching, patient care and the advancement of the art and science of medicine, locally, nationally and globally. Weill Cornell, which is a principal academic affiliate of NewYork-Presbyterian Hospital, offers an innovative curriculum that integrates the teaching of basic and clinical sciences, problem-based learning, office-based preceptorships, and primary care and doctoring courses. Physicians and scientists of Weill Cornell Medical College are engaged in cutting-edge research in areas such as stem cells, genetics and gene therapy, geriatrics, neuroscience, structural biology, cardiovascular medicine, transplantation medicine, infectious disease, obesity, cancer, psychiatry and public health - and continue to delve ever deeper into the molecular basis of disease in an effort to unlock the mysteries of the human body in health and sickness. In its commitment to global health and education, the Medical College has a strong presence in places such as Qatar, Tanzania, Haiti, Brazil, Austria and Turkey. Through the historic Weill Cornell Medical College in Qatar, the Medical College is the first in the U.S. to offer its M.D. degree overseas. Weill Cornell is the birthplace of many medical advances - including the development of the Pap test for cervical cancer, the synthesis of penicillin, the first successful embryo-biopsy pregnancy and birth in the U.S., the first clinical trial of gene therapy for Parkinson's disease, the first indication of bone marrow's critical role in tumor growth, and most recently, the world's first successful use of deep brain stimulation to treat a minimally-conscious brain-injured patient. For more information, visit www.med.cornell.edu.

Weill Cornell Medical College

---

---

	The Definitive Guide to Prostate Cancer: Everything You Need to Know about Conventional and Integrative Therapies by Dr. Aaron Katz (Author) The complete guide to coping with prostate cancer, with expert health advice for every man This comprehensive handbook gives men the vital information they need to effectively navigate every step of dealing with prostate cancer. A newly diagnosed cancer patient faces a mind-numbing array of treatment options, including medical therapies that carry serious side effects—and determining the right course of action is an overwhelming task. In simple yet scientific terms, this book empowers readers with the tools they need to proactively fight cancer by making the most informed treatment decisions possible.  With groundbreaking developments recently emerging in both conventional and holistic prostate cancer research, it is imperative that men fighting this disease have the absolute...
	Dr. Patrick Walsh's Guide to Surviving Prostate Cancer, Second Edition by Patrick C. Walsh (Author), Janet Farrar Worthington (Author) EVERY MAN NEEDS THIS BOOK! Each year, more than 200,00 American men are diagnosed with prostate cancer. The good news is that more men are being cured of this disease than ever before. Now in a revised second edition, this lifesaving guide by Dr. Patrick Walsh and ard-winning science writer Janet Farrar Worthington offers a message of hope to every man facing this illness. Prostate cancer is a different disease in every man--which means that the right treatment varies for each man. Giving you a second opinion from the world's top experts in surgery, pathology, urology, and radiation and medical oncology, this book helps you determine the best plan for you. Learn: What causes prostate cancer--your risk factors, including heredity, diet, and environment How some simple changes in...
	The Decision: Your prostate biopsy shows cancer. Now what?: Medical insight, personal stories, and humor by a urologist who has been where you are now. by John C. McHugh M.D. (Author), Johanna C. Craig Ph.D. (Editor), Graham L. Gaines (Editor), William P. Black (Editor), Travis Massey (Editor), Sandra B. Brim Ph.D. (Editor), Janice K. Watts (Editor) Over 200,000 times a year in the U.S. a patient will leave his urologist's office having been told he has prostate cancer. What the patient thought to be a disease of old men from which they do not die, now becomes a very complicated and frustrating dilemma about which treatment to pursue. "The Decision" offers the reader an insider's view to the key issues necessary for a well thought-out treatment plan peculiar only to him. Being a urologist who treats prostate cancer and having had the disease as well, uniquely positions the author in offering guidance to the newly diagnosed prostate cancer patient. Dr. McHugh outlines a novel and multifaceted approach, using an eclectic mix of medical insight ,personal stories and humor, to aid the reader in making his "Decision." The US Review of...
	Winning the Battle Against Prostate Cancer: Get the Treatment That is Right for You by Gerald Chodak (Author) The range of controversial therapies and treatments for prostate cancer is greater than that of any other cancer affecting men. Many of the current books on prostate cancer suffer from considerable bias promoting one treatment over another without good scientific evidence. Winning the Battle Against Prostate Cancer is an unbiased and up-to-date look at prostate cancer treatments and therapies, resolving the problem of contradictory and incomplete information. Dr. Chodak outlines the pros and cons of all reasonable treatment options, recognizing that men and their families need more than just the facts — they are concerned not only with their survival but also what life will be like after treatment. This book offers empathetic insight into the impact of the disease on day-to-day...
	You Can Beat Prostate Cancer: And You Don't Need Surgery to Do It by Robert J. Marckini (Author) The task of choosing the right prostate cancer treatment is daunting. It is further complicated by conflicting information the patient receives from physicians and the Internet. This book is written by a prostate cancer survivor who now runs an internatio
	Johns Hopkins Patients' Guide to Prostate Cancer (The Johns Hopkins Patients' Guide) by Arthur L. Burnett (Author) The Johns Hopkins Patients Guide to Prostate Cancer is a concise, easy-to-follow how to guide that puts you on a path to wellness by explaining prostate cancer treatments from start to finish. It guides you through the overwhelming maze of treatment decisions, simplifies the complicated schedule that lies ahead, and provides valuable tools to help you to put together your plan of care. Empower yourself with accurate, understandable information that will give you the ability to confidently participate in the decision making about your care and treatment.
	Prostate Cancer Survivors Speak Their Minds: Advice on Options, Treatments, and Aftereffects by Arthur L. Burnett II (Author), Norman Morris (Author) Personal stories show men how to make the right decisions for themselves, with medical insights from a leading Johns Hopkins authority on prostate cancerIf you or someone you know has been diagnosed with prostate cancer, you want to know the facts about treatment options as well as what to expect through the process of treatment and recovery.Written by Dr. Arthur L. Burnett, II. one of the world's most distinguished authorities on prostate cancer and veteran CBS News journalist and prostate cancer survivor, Norman Morris, Prostate Cancer Survivors Speak Their Minds gives you the information you need through the experiences of men who have had prostate cancer. Dr. Burnett speaks openly and honestly about prostate cancer options, treatments, and aftereffects and shares stories of both...
	Prostate and Cancer: A Family Guide to Diagnosis, Treatment, and Survival by Sheldon Marks MD (Author) Prostate cancer is one of the most common cancers affecting American men, with over 186,000 new cases diagnosed in the United States annually; 1 in 6 men will be diagnosed with prostate cancer during his lifetime. Renowned prostate cancer specialist Sheldon Marks offers the definitive guide for men concerned about or diagnosed with prostate cancer, and for their families.Since the third edition (2003), there have been significant changes in treatment and resources. Working with Dr. Judd Moul, the Chairman of Urology at Duke and one of the world’s top experts on prostate cancer, Marks provides the most up-to- date information on diagnosis, treatment, and common questions.
	Dr. Peter Scardino's Prostate Book, Revised Edition: The Complete Guide to Overcoming Prostate Cancer, Prostatitis, and BPH by Peter T. Scardino M.D. (Author), Judith Kelman (Author) Newly revised, with up-to-the-minute findings: the potentially lifesaving guide to prostate health by one of the world's foremost urologists Although most men know little about their prostate glands, an overwhelming majority will be affected by prostate problems at some time in their lives. In this groundbreaking book, now updated to include the latest medical break-throughs, world-renowned urology expert Dr.Peter Scardino arms men with the information they need to battle prostate cancer, prostatitis, and benign prostate enlargement (BPH). This updated edition includes new information on the role genetics may play, hormone replacement therapy, new treatments for prostatitis, and more. With clear illustrations and charts throughout, this book covers everything men should...
	Invasion of the Prostate Snatchers: An Essential Guide to Managing Prostate Cancer for Patients and their Families by Ralph Blum (Author), Mark M.D. Scholz (Author) Radical prostatectomy is still the most widely recommended treatment for prostate cancer. Yet, according to a recent study, only one out of every forty-eight men who undergo this debilitating procedure survives longer than those who forgo surgery. Invasion of the Prostate Snatchers reports the latest thinking on prostate cancer management in clear, easy-to-understand prose. In a unique collaboration, a patient and his doctor provide a new perspective on living with this disease. Ralph Blum’s surprisingly entertaining twenty-year journey and eventual decision to treat his cancer as a “chronic condition,” together with Dr. Mark Scholz’s presentation of the newest scientific evidence, will liberate thousands of newly diagnosed men to pursue a noninvasive approach and thereby preserve...